The Claim

Plasma GFAP levels increase approximately 12 years before the clinical onset of mild cognitive impairment in individuals who later develop Alzheimer’s disease, and also increase in individuals who develop non-Alzheimer’s cognitive impairment, indicating that plasma GFAP elevation reflects general neuroinflammation rather than Alzheimer’s-specific pathology.

Source: Plasma biomarker trajectories across Alzheimer’s clinical onset: a 17-year prospective study

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
64score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

Plasma GFAP levels rise about 12 years before cognitive symptoms appear in people who eventually develop Alzheimer’s disease, and also rise in people who develop other forms of cognitive decline, showing that this biomarker is linked to general neuroinflammation, not Alzheimer’s-specific brain changes.

See the scientific wording

Plasma GFAP levels rise approximately 12 years before clinical onset of mild cognitive impairment in individuals who develop Alzheimer’s disease, but also increase in those who develop non-Alzheimer’s cognitive impairment, indicating it reflects general neuroinflammation rather than Alzheimer’s-specific pathology.

Why this might work

When brain tissue becomes inflamed, star-shaped brain cells called astrocytes react by swelling and producing more GFAP protein. This protein leaks into the bloodstream, where it can be measured years before memory problems appear, no matter what causes the brain inflammation.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: Plasma biomarker trajectories across Alzheimer’s clinical onset: a 17-year prospective study

    This study found that a blood marker called GFAP goes up about 12 years before memory problems start, whether people will get Alzheimer’s or another kind of brain decline. That means GFAP isn’t just signaling Alzheimer’s—it’s showing general brain inflammation from many causes.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.